Products

EchoMeasure
iCardio.ai
Cardiology AI
EchoMeasure by iCardio.ai is an FDA-cleared AI software that automates the analysis of cardiac ultrasound images, providing automated measurements, view classification, and preliminary reporting to enhance diagnostic accuracy and efficiency for cardiologists and sonographers.
CardioVision
Icardio.Ai
Cardiology AI
CardioVision by iCardio.ai is an FDA-cleared AI software that provides adjunctive diagnostic support for detecting moderate to severe aortic stenosis from echocardiogram images, streamlining cardiovascular diagnostics.
iCardio.ai
iCardio.ai
Cardiology AI
iCardio.ai provides FDA-cleared AI software for automated echocardiographic interpretation, offering automated measurements, disease detection (e.g., aortic stenosis), and image quality assessment to streamline cardiac diagnostics.

See all 3 products →

About iCardio.ai

iCardio.ai is a Los Angeles-based healthcare AI company specializing in machine learning and deep learning algorithms for the analysis of ultrasound applications, with a primary focus on echocardiography (heart ultrasounds). The company aims to revolutionize heart disease detection and treatment by providing accessible, accurate, and automated interpretation of cardiac imaging. They have developed an AI system, trained on a proprietary dataset of over 200 million images, to automatically interpret echocardiograms.

iCardio.ai’s flagship product, EchoMeasure™, received U.S. Food and Drug Administration (FDA) 510(k) clearance in October 2024. This software provides an automated, comprehensive imaging workflow and preliminary reporting tool for echocardiographic interpretation, including view classification, quality checks, and automated measurements of cardiac anatomical structures and quantities. Additionally, their AI-based aortic stenosis detection tool, CardioVision™, received FDA Breakthrough Device Designation in February 2024, addressing unmet needs in cardiac diagnostics. The company is also working on EchoGPT, an AI-powered tool capable of autonomously generating complete echocardiography reports.

iCardio.ai has established significant partnerships with major ultrasound vendors and healthcare organizations, including GE Healthcare, Butterfly Network, UltraLinQ, Viz.ai, and Abbott. These collaborations aim to integrate iCardio.ai’s technology into existing ultrasound platforms and PACS systems, broadening the accessibility and utility of echocardiography AI for clinicians globally.

Focus Areas

Artificial Intelligence Deep Learning Echocardiography Ultrasound Interpretation Cardiac Imaging Medical Diagnostics HealthTech Machine Learning

Business Intelligence

TechnologyMachine learning and deep learning algorithms for ultrasound interpretation, cloud-native or on-premise server deployment, API for integration

What Physicians Need to Know

Specialization
iCardio.ai specializes in applying machine learning and deep learning algorithms to ultrasound, with a primary focus on transthoracic echocardiography. They aim to automate all aspects of echocardiographic interpretation. [1, 2, 3, 6, 13]
Key Products & Features
Their flagship product, EchoMeasure™, provides automated, comprehensive imaging workflow and preliminary reporting, including dozens of critical heart measurements. [2, 4, 9, 10, 11] CardioVision™ is an FDA-cleared AI software that acts as a diagnostic aid for detecting aortic stenosis from a single ultrasound clip and has received FDA Breakthrough Device Designation. [1, 2, 4, 5, 9, 12] They also offer EchoCheck for image quality and view classification, and EchoGPT for image-to-text descriptions of ultrasound images. [1, 9]
Technology Stack
iCardio.ai leverages a proprietary dataset of over 200 million echocardiographic images for training its AI models, making it one of the largest-scale radiological AI products globally. [1, 2, 3, 7, 9, 13] They utilize NVIDIA Clara Holoscan to run their multi-AI pipelines in real-time at the edge, enabling concurrent execution of over 60 machine learning algorithms. [7]
Regulatory Status
EchoMeasure™ has received U.S. Food and Drug Administration (FDA) 510(k) clearance. [2, 6, 9, 14] CardioVision™ has received FDA 510(k) clearance and FDA Breakthrough Device Designation for its aortic stenosis detection algorithm. [1, 2, 4, 5, 6, 9, 12]
Partnerships
iCardio.ai has established significant partnerships with major healthcare companies, including a multi-year collaboration with GE Healthcare to integrate its technology into GE ultrasound platforms. [2, 13] They also partner with UltraLinQ, SARC MedIQ for PACS integration, Viz.ai for care coordination, and Abbott for developing AI applications for intracardiac echocardiography. [2, 3, 5, 8, 14] Additionally, they have joined Butterfly Garden to deploy their cardiac AI suite on Butterfly Network's portable ultrasound platform. [11]
Physician Tip

iCardio.ai's solutions are designed to enhance diagnostic accuracy and efficiency in echocardiography, potentially leading to earlier diagnosis and improved patient outcomes, especially for conditions like aortic stenosis. [2, 5, 12] The automated measurements and preliminary reports can significantly reduce the time spent on repetitive tasks, addressing issues like Work-Related Musculoskeletal Disorders (WRMSDs) among sonographers. [4] The AI tools also provide objective image quality assessment, which can help maintain IAC accreditation and ensure high-quality ultrasound images. [1] Their technology is being integrated into various ultrasound platforms and PACS systems, aiming for seamless integration into existing clinical workflows. [1, 3, 11] The ability to detect structural heart disease and aortic stenosis from a single ultrasound clip, even in point-of-care settings, can empower non-specialists and facilitate timely referrals. [1, 5, 12]

iCardio.ai offers a simple and straightforward API for easy integration of their AI algorithms into enterprise PACS workflows and hardware. [1, 9] They are actively partnering with ultrasound companies, PACS vendors, and healthcare systems to deliver their technology directly to clinicians. [1, 2, 3, 9, 11, 13]

Products by iCardio.ai

3 products in the directory

EchoMeasure
iCardio.ai
Cardiology AI
EchoMeasure by iCardio.ai is an FDA-cleared AI software that automates the analysis of cardiac ultrasound images, providing automated measurements, view classification, and preliminary reporting to enhance diagnostic accuracy and efficiency for cardiologists and sonographers.
CardioVision
Icardio.Ai
Cardiology AI
CardioVision by iCardio.ai is an FDA-cleared AI software that provides adjunctive diagnostic support for detecting moderate to severe aortic stenosis from echocardiogram images, streamlining cardiovascular diagnostics.
iCardio.ai
iCardio.ai
Cardiology AI
iCardio.ai provides FDA-cleared AI software for automated echocardiographic interpretation, offering automated measurements, disease detection (e.g., aortic stenosis), and image quality assessment to streamline cardiac diagnostics.

What the Web Says

iCardio.ai is a company that develops AI-powered software for automating the interpretation of echocardiograms, aiming to improve diagnostic accuracy and efficiency in cardiology. Their products, such as EchoMeasure™ and CardioVision™, have received FDA clearance and Breakthrough Device Designation, respectively. The company leverages a large dataset of echocardiographic images and collaborates with world-leading cardiologists and AI scientists. While there are no direct user reviews on major platforms like G2, Glassdoor, or Capterra specifically for iCardio.ai's products or as an employer, discussions on Reddit and information from other sources highlight the potential benefits and challenges of AI in echocardiography.

Overall: Mixed

Strengths

  • Automates echocardiography measurements and analysis, reducing manual effort and time for clinicians.
  • Aims to improve accuracy and consistency by reducing human error and inter-observer variability.
  • Integrates into existing cardiac imaging and reporting workflows, streamlining the process.
  • FDA-cleared AI tools for automating echocardiography measurements and detecting aortic stenosis.
  • Partnerships with major healthcare organizations like GE Healthcare, UltraLinQ, and SARC MedIQ.
  • Leverages a proprietary database of over 200 million ultrasound images for robust AI development.

Limitations

  • Lack of direct user reviews on major platforms like G2, Glassdoor, and Capterra makes it difficult to assess real-world user satisfaction and employer sentiment.
  • General concerns about AI in medicine, such as accuracy, training, trust in technology, and the potential impact on the role of healthcare professionals.
  • Potential for AI to be confidently incorrect in interpretations, as seen in some AI ECG tools.
  • Challenges in integrating AI tools into existing workflows and addressing potential issues like accuracy and training.

Based on reviews from: Reddit, iCardio.ai official website, Product Hunt, SaaSHub, SoftwareSuggest, G2, RadAISlice, MedAxiom

Last updated: 2026-10-19

Videos

News, demos, and interviews about iCardio.ai.

Loading videos...

Videos load interactively. If none appear, search YouTube for iCardio.ai →

View all on YouTube

Press & Coverage

covefund.com
iCardio.ai Closes $4.5M Strategic Financing Led by Cedars-Sinai
iCardio.ai secured $4.5 million in strategic financing, led by Cedars-Sinai Technology Ventures, to advance AI in echocardiography and gain extensive access to Cedars-Sinai's cardiac imaging dataset.
2026-04
mobihealthnews.com
iCardio.ai gets FDA 510(k) clearance for AI echocardiography
iCardio.ai received FDA 510(k) clearance for its AI software, EchoMeasure, which interprets echocardiography data for comprehensive imaging workflow and autonomous preliminary reporting, with algorithms capable of detecting valvular heart disease.
2024-10
icardio.ai
iCardio.ai Receives FDA Breakthrough Designation for Automated Detection of Aortic Stenosis
iCardio.ai was granted FDA Breakthrough Device Designation for its machine-learning system designed to detect moderate and severe Aortic Stenosis using handheld ultrasound devices.
2024-02
icardio.ai
iCardio.ai Announces Major Additional Funding through Partnership with BSD Enterprises
iCardio.ai closed a strategic funding round led by BSD Enterprises, which will be used to expand its AI capabilities, increase engineering headcount, and promote its flagship API service for intelligent echocardiographic analysis.
2021-06
icardio.ai
iCardio.ai Receives Second FDA 510(k) Clearance, CardioVision™ for Aortic Stenosis
iCardio.ai announced its second FDA 510(k) clearance for CardioVision™, an AI software that automatically detects aortic stenosis from a single parasternal long axis (PLAX) clip.
2025-11
icardio.ai
iCardio.ai Joins Butterfly Garden to Deploy Its Cardiac AI Suite on Butterfly Network's Imaging Platform
iCardio.ai partnered with Butterfly Network to integrate its cardiac ultrasound AI tools into Butterfly's handheld ultrasound system, aiming to make AI in ultrasound more accessible to healthcare practitioners.
2023-11
icardio.ai
iCardio.ai Partners with Viz.ai to Revolutionize Aortic Stenosis Detection and Treatment Pathways
iCardio.ai collaborated with Viz.ai to integrate its AI-driven aortic stenosis detection algorithm with Viz.ai's Cardio Suite, aiming to improve early diagnosis and treatment pathways for patients.
2024-04
icardio.ai
iCardio.ai Partners with deepc to Distribute AI Algorithms in Europe
iCardio.ai announced a partnership with deepc, a European AI algorithm distributor, to make its AI-driven ultrasound interpretation tools accessible to healthcare systems in Europe.
2024-02

Frequently Asked Questions

iCardio.ai offers several AI-powered solutions for echocardiography interpretation, including EchoMeasure™, CardioVision™, EchoCheck, Quantitative, Qualitative, and EchoGPT. EchoMeasure™ provides automated linear and volumetric measurements of the heart, while CardioVision™ is an FDA-cleared AI software that aids in the detection of Aortic Stenosis. EchoCheck tracks image quality and completeness, Quantitative offers automated measurements, Qualitative detects structural heart disease, and EchoGPT is an image-to-text AI tool for describing ultrasound images.
iCardio.ai prioritizes compliance and regulatory adherence, evidenced by their FDA 510(k) clearances for EchoMeasure™ and CardioVision™. CardioVision™ also received Breakthrough Device Designation from the FDA for its ability to automatically detect aortic stenosis. Their software is designed to process previously acquired DICOM-compliant cardiac ultrasound images and can be deployed on secure cloud or on-premise servers, similar to predicate devices.
iCardio.ai's pricing model is not explicitly stated as a fixed cost. Instead, they indicate that after a trial period, they work with hospitals to determine the best pricing model based on the volume of studies processed and the value created. They aim to integrate into existing ultrasound and PACS systems and offer feasibility trials to demonstrate product value.
While specific details on technical assistance and training programs are not extensively detailed, iCardio.ai encourages direct contact for inquiries and integration into existing pipelines. They have also partnered with distributors like UltraLinQ, which offers FAQs and troubleshooting for iCardio.ai within its platform.
iCardio.ai has formed significant partnerships with various entities in the HealthTech and medical imaging industries. These include collaborations with GE Healthcare, UltraLinQ, SARC MedIQ, deepc, and Abbott. These partnerships aim to integrate iCardio.ai's technology into ultrasound platforms, PACS systems, and for the development of AI applications for imaging devices used in cardiac arrhythmia treatments.
iCardio.ai is a privately held company that has secured strategic financing, including a $4.5 million round led by Cedars-Sinai Technology Ventures in April 2026. They have also received early-stage funding through accelerator programs like HeartX. The company is actively generating revenue and has access to a large proprietary dataset of over 200 million ultrasound images, which contributes to its stability and growth.
iCardio.ai's technology addresses challenges in echocardiography interpretation by automating various aspects of the process, aiming to improve efficiency and reduce variability. Their solutions accelerate interpretation time by up to three times, automate analysis for both normal and diseased patients, and provide insights into image quality. By leveraging AI and deep learning algorithms trained on a vast database of images, iCardio.ai aims to provide accurate and consistent interpretation, which can lead to earlier diagnoses and improved patient outcomes.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.